Chair of Biochemistry and Molecular Biology

Publications

2025

Dehmer M.*, Trunk K.*, ..., Eilers M., Büchel G. (2025). USP11/TCEAL1 complex promotes transcription elongation to sustain oncogenic gene expression in neuroblastoma. Genes Dev. https://doi.org/10.1101/gad.352166.124, PMID: 40250979

Grunewald, L., ..., Büchel, G.,…Kunkele, A. (2025). Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy. Pharmacol Res, 212, 107608. https://doi.org/10.1016/j.phrs.2025.107608, PMID: 39828101

2024

Vidal, R., ..., Büchel, G. (2024). Association with TFIIIC limits MYCN localisation in hubs of active promoters and chromatin accumulation of non-phosphorylated RNA polymerase II. Elife, 13. https://doi.org/10.7554/eLife.94407, PMID:  39177021

Papadopoulos, D., Ha, S. A., Fleischhauer, D., ..., Büchel, G., Vos, S. M., & Eilers, M. (2024). The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex. Mol Cell, 84(11), 2070-2086 e2020. https://doi.org/10.1016/j.molcel.2024.04.007, PMID: 38703770

2023

Alborzinia H, …, Büchel G, …, Friedmann Angeli JP (2023). LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma. EMBO Mol Med.; 15(8):e18014. doi: 10.15252/emmm.202318014, PMID: 37435859.

2021

Kalogirou C, …, Büchel G, …, Schulze A. (2021) MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. Nat Commun.;12(1):5066. doi: 10.1038/s41467-021-25325-9, PMID: 34417456.

Roeschert I, …, Chesler L, Büchel G* and Eilers M* (2021) Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma. Nature Cancer, 2021. doi: 10.1038/s43018-020-00171-8, PMID: 33768209. *joint senior authors

Wolpaw, A. J., Bayliss, R., Büchel, G., …, Mosse, Y. P. (2021). Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. Cancer Res 81, 1627-1632. doi: 10.1158/0008-5472.CAN-20-3108. PMID: 33509943.

2019

Herold, S.*, Kalb, J. *, Büchel, G. *, …, Eilers, M. (2019). Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase. Nature 567, 545-549. doi: 10.1038/s41586-019-1030-9. PMID: 30894746 *Joint first authors

2018

Batzke, K., Büchel, G., Hansen, W., and Schramm, A. (2018). TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy. Int J Mol Sci 19. doi: 10.3390/ijms19030718. PMID: 29498681.

2017

Büchel, G., Carstensen, A., Mak, K.Y., …, Eilers, M. (2017). Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle. Cell Rep 21, 3483-3497. doi: 10.1016/j.celrep.2017.11.090. PMID: 29262328.

2016

Büchel, G., …, Hansen, W., and Schramm, A. (2016). Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma. Oncoimmunology 5, e1131378. doi: 10.1080/2162402X.2015.1131378. PMID: 27467948

2013

Schramm, A., …, Büchel, G., …, Schulte, J.H. (2013). Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. Int J Cancer 132, E106-115. doi: 10.1002/ijc.27787. PMID: 22907398.

Publications (in pre-print / in revision)

  1.  Müller, M., …, Eilers M., Büchel G. The MYCN/Aurora-A complex is a cyclin activating kinase for CDK12. (under review).

Preprint available: https://www.biorxiv.org/content/10.1101/2025.01.15.633177v1

  1. Leen, E., …, Büchel G., Bayliss R. Mechanism of Interaction Between the Transactivation Domain of N-MYC and the DNA-Binding Surface of TFIIIC5 (under review).

Preprint available: https://www.biorxiv.org/content/10.1101/2024.10.19.619198v1